Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy

This study is investigating whether GLP-1 receptor agonist medications (such as semaglutide, the active ingredient in Ozempic/Wegovy) can help men with prostate cancer manage weight gain and related health problems caused by hormone therapy (androgen deprivation therapy, or ADT). **You may be eligible if...** - You have a prostate cancer diagnosis - You are currently receiving or about to start hormone therapy (ADT) - You have a BMI of 30 or higher, OR a BMI of 27 or higher with high blood pressure, type 2 diabetes, sleep apnea, or high cholesterol **You may NOT be eligible if...** - You have type 1 diabetes - You are already taking a GLP-1 medication - You are under 18 - You have a history of pancreatitis - You or a family member has had medullary thyroid cancer or a condition called multiple endocrine neoplasia type 2 Talk to your doctor to see if this trial is right for you.